Helixor P

Helixor P is a prescription‑only injectable solution that contains a liquid extract of Viscum album subsp. austriacum var. pinus sylvestris (mistletoe) prepared at a 1:20 ratio with extraction solvents. The product is supplied as a sterile subcutaneous preparation and is marketed in the European Union for use under medical supervision. Helixor P is classified as a herbal extract with immunomodulatory and antineoplastic properties. It is administered by a qualified professional.

Helixor P is used as an adjunctive therapy in oncology, primarily to support patients undergoing conventional cancer treatments and to address therapy‑related symptoms.

- As an adjunct to chemotherapy, radiotherapy, or surgery for various solid tumors. - To help alleviate treatment‑related fatigue, weight loss, and reduced appetite. - For potential enhancement of immune response during cancer therapy. - As part of supportive care aimed at improving patients’ quality of life. - In palliative settings where disease control is limited but symptom management is needed.

Side‑effect profiles for Helixor P reflect its biologically active mistletoe constituents and are reported from clinical observations; most reactions are mild and reversible, while rare serious events require medical attention.

Common: - Mild injection‑site reactions such as redness, swelling, or tenderness. - Transient flu‑like symptoms including fever, chills, or headache. - Temporary increase in heart rate or mild hypertension. - Nausea or mild gastrointestinal discomfort. - Local skin irritation or pruritus at injection site.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis. - Significant hypotension or cardiovascular instability. - Hepatic enzyme elevations indicating liver stress. - Severe leukopenia or neutropenia observed in rare cases.

When prescribing Helixor P, clinicians should evaluate patient history and monitor for specific safety considerations.

- Contraindicated in patients with known hypersensitivity to mistletoe extracts. - Use caution in individuals with autoimmune disorders or chronic inflammatory conditions. - Not recommended during pregnancy or lactation due to insufficient safety data. - Baseline and periodic assessment of blood pressure and heart rate is advisable. - Monitor liver function tests during prolonged therapy. - Evaluate for potential interactions with immunosuppressive agents. - Adjust dosage or discontinue if severe adverse reactions occur.

Helixor P may influence the activity of certain medications; awareness of possible interactions helps ensure safe combined use.

Avoid: - Concurrent use with high‑dose immunosuppressants such as cyclosporine or tacrolimus.

Use with caution: - Combination with chemotherapy agents; monitor for enhanced toxicity. - Concurrent administration of anticoagulants; observe for changes in bleeding risk. - Use with other herbal preparations that affect immune function. - Co‑administration with beta‑blockers; watch for additive cardiovascular effects. - Concomitant use with vaccines; assess timing to avoid immune interference.